In vivo CAR-T therapy has reached a genuinely different regulatory moment: IASO Bio’s IASO208, a CD20-targeting candidate built on its InTelliCAR lentiviral vector platform, now holds active IND clearances in both the United States and China simultaneously. The FDA cleared the IND implicitly in September 2026; the NMPA followed this month via China’s 30-day expedited review pathway, one of China’s expedited IND review pathways. That dual clearance is the structural move: IASO can now build on its China IIT dataset to initiate Phase Ib work in the United States, with larger studies planned across both jurisdictions.
That dataset is thin but legible. Eleven patients have been dosed in the ongoing IIT in China, all without apheresis or lymphodepleting conditioning, receiving a single intravenous infusion. Early data demonstrated favorable tolerability and promising anti-tumor activity, for the data to earn an oral presentation slot at the 2026 ASH Annual Meeting (Abstract #705). Eleven patients is not a signal; it is enough to anchor a Phase Ib design and satisfy regulators that proceeding is reasonable. All currently approved CAR-T therapies are ex vivo, meaning T cells are engineered outside the body before reinfusion, so the in vivo approach, where the vector does the reprogramming inside the patient, still carries substantial unknowns at scale.
The regulatory path IASO used matters as much as the clearances themselves. China’s 30-day expedited IND track is a relatively recent mechanism for innovative candidates with urgent development rationale; getting IASO208 through it confirms the NMPA treated the in vivo CAR-T construct as scientifically credible, not just administratively complete. IASO has an established track record with the NMPA: its ex vivo BCMA-targeting product equecabtagene autoleucel has been approved in China for relapsed/refractory multiple myeloma, giving the company real CMC and regulatory infrastructure to draw on for IASO208’s development.
The practical question now is whether the U.S. Phase Ib can generate safety and efficacy data in B-NHL patients that holds up against the more demanding FDA review a registrational filing would require. The ASH oral presentation is an early public look at whether the 11-patient IIT dataset supports the dual-jurisdiction development path IASO has now opened.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
